The new recombinant subunit vaccine against bluetongue virus-3 in Europe is expected to receive emergency authorisation. Verovaccines' rapid platform technology enables cost- and time-efficient vaccine development.

Following the validation of its new vaccine and manufacturing platforms, Verovaccines is expanding its portfolio with new mono- and combination vaccines.

Purenum will operate as a subsidiary of FARCO-PHARMA and will continue to advance its work in the area of research & development.

ActiTrexx GmbH has closed a Series A funding round, during which it raised €3.5 million. The recently funded biotech company based in the Germany city of Mainz develops a cell therapy against transplant rejections. Clinical trials are due to start as early as this year.

Verovaccines GmbH develops novel yeast-based veterinary vaccines. The vaccines can be used against a variety of pathogens in different animal species. The vaccine development is funded by the “Gründungsoffensive Biotechnologie GO-Bio” (Founding Initiative Biotechnology) of the Federal Ministry of Education and Research (BMBF). Dr Hanjo Hennemann, CEO and co-founder of Verovaccines, explains how the vaccine works and what the next steps in vaccine development will be:

The company’s patent-protected technology platform for the development of multivalent yeast‑based vaccines has attracted further investors.

The Berlin-based research team first had the idea for a new kind of drug against atrial fibrillation more than ten years ago. They have been supported in creating the spin-off and carrying out initial clinical trials by the Federal Ministry of Education and Research (BMBF) and private investors.

The US-American manufacturer Proteintech is expanding its portfolio of next generation antibody technology via acquisition. The Munich-based start-up ChromoTek is the market leader in particularly small and versatile antibodies.

The Munich-based start-up team have managed to impress with their business plan for a diagnostics company. The highly-sensitive diagnostics allow the parallel expression analysis of individual cells and can contribute to tailor-made approaches to therapy.

In Germany alone, around 270,000 people suffer a stroke each year. Doctors are under enormous pressure in their choice of therapy. A computer model should now assist them and make custom-fit decisions possible.

Just four months after starting their collaboration to look for a SARS-CoV-2 vaccine, the Mainz-based biotech firm BioNTech and the US Pfizer pharmaceutical group have announced the selection of a highly-promising main candidate and the start of the global phase 2/3 approval trial.

This Freiburg-based start-up wants to use a capital increase of EUR 16.3 million to bring its mini-lab for testing for corona viruses on to the market before the end of 2020.

41 Project proposals have made it through the first selection round and are now to receive funding for the conceptual phase.

Neurimmune and Ethris announce their exclusive partnership for developing immunotherapy. Clinical trials are set to start by the end of 2020.

Mainz-based biotech joins the race to develop a vaccine against coronavirus. Partnering with US pharmaceutical giant Pfizer for development and worldwide marketing.

Biotech secures new US partner: Recent merger with Canopy Biosciences followed by Core Diagnostics takeover.